LCTX · Lineage Cell Therapeutics, Inc.
$1.08
-0.02 (-1.82%)
At close · Sep 4
View the 10-K filed Mar 5, 2026
Customer concentration
— top 2 customers 92% of revenue
2 customers — 92% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”
One customer — 92% of revenue (the year ended December 31, 2024)
“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
Market Cap
$273.14M
Shares
252.91M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Brian M. Culley | Chief Executive Officer and Former Interim Chief Financial Officer | $1,349,913 |
| Brian Culley | CEO | $1,349,913 |
| Chase C. Leavitt | Former General Counsel and Corporate Secretary | $752,952 |
| Brandi Roberts | Former Chief Financial Officer | $668,252 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Brandi Roberts | Former Chief Financial Officer | $947,963 |
| Brian Culley | CEO | $772,742 |
| Brian M. Culley | Chief Executive Officer and Former Interim Chief Financial Officer | $772,742 |
| Edward D. Wirth | III, M.D., Ph.D. Former Chief Medical Officer | $694,792 |
| Chase C. Leavitt | Former General Counsel and Corporate Secretary | $599,098 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Brian M. Culley | Chief Executive Officer | $2,862,707 |
| Brian Culley | CEO | $2,862,707 |
Key facts
CIK
876343
CUSIP
53566P109
13F (30d)
79 filings
79 filers
Visit website
Investor relations